Stockreport

CorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated Melinta integration and DefenCath momentum [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF CEO Joseph Todisco highlighted the completion and rapid integration of the Melinta Therapeutics acquisition, describing it as "transformational for CorMedix creating a [Read more]